{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:22:43Z","timestamp":1768094563839,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T00:00:00Z","timestamp":1573084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40258-019-00523-1","type":"journal-article","created":{"date-parts":[[2019,11,7]],"date-time":"2019-11-07T05:41:21Z","timestamp":1573105281000},"page":"109-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost Effectiveness of Secukinumab Versus Other Biologics and Apremilast in the Treatment of Active Psoriatic Arthritis in Germany"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4262-8344","authenticated-orcid":false,"given":"Afschin","family":"Gandjour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Ostwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,7]]},"reference":[{"issue":"3","key":"523_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landew\u00e9 R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Ca\u00f1ete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"key":"523_CR2","unstructured":"Elsevier Health Analytics. \u00dcbersichtsbericht der Ergebnisse: Versorgungsforschung Psoriasis (Pso), Psoriasisarthritis (PsA) und axiale Spondyloarthritis (AxSpA) in Deutschland; eine retrospektive Analyse auf Routinedaten; 2017."},{"key":"523_CR3","unstructured":"Cosentyx. Summary of product characteristics. Last updated: 25\/10\/2018. \nhttps:\/\/www.ema.europa.eu\/documents\/product-information\/cosentyx-epar-product-information_en.pdf\n\n (accessed 10 Aug 2019)."},{"issue":"9999","key":"523_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"14","key":"523_CR5","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"key":"523_CR6","unstructured":"Gemeinsamer Bundesausschuss. Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII - Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V\u2014Secukinumab (neues Anwendungsgebiet). Gemeinsamer Bundesausschuss; 2. Juni 2016."},{"key":"523_CR7","unstructured":"Gemeinsamer Bundesausschuss. Tragende Gr\u00fcnde zum Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII \u2013 Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V\u2014Ixekizumab (neues Anwendungsgebiet: Psoriasis-Arthritis). Gemeinsamer Bundesausschuss; 16. August 2018."},{"issue":"7","key":"523_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40273-018-0674-x","volume":"36","author":"V Buchanan","year":"2018","unstructured":"Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018;36(7):867\u201378.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"523_CR9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/13696998.2017.1384737","volume":"21","author":"R Goeree","year":"2018","unstructured":"Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018;21(2):163\u201373.","journal-title":"J Med Econ"},{"issue":"16","key":"523_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12962-018-0162-3","volume":"16","author":"T Purmonen","year":"2018","unstructured":"Purmonen T, Puolakka K, Bhattacharyya D, Jain M, Martikainen J. Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active psoriatic arthritis: a Finnish perspective. Cost Eff Resour Alloc. 2018;16(16):56.","journal-title":"Cost Eff Resour Alloc"},{"key":"523_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","volume":"75","author":"I McInnes","year":"2016","unstructured":"McInnes I, Nash P, Ritchlin C, et al. THU0437\u2005Secukinumab for the treatment of psoriatic arthritis: comparative effectiveness results versus licensed biologics and apremilast from a network meta-analysis. Ann Rheum Dis. 2016;75:348\u20139.","journal-title":"Ann Rheum Dis"},{"key":"523_CR12","volume-title":"GKV-Arzneimittel-Schnellinformation f\u00fcr Deutschland GKV-Arzneimittel-Schnellinformation f\u00fcr Deutschland","author":"Spitzenverband Bund der Krankenkassen","year":"2018","unstructured":"Spitzenverband Bund der Krankenkassen. GKV-Arzneimittel-Schnellinformation f\u00fcr Deutschland GKV-Arzneimittel-Schnellinformation f\u00fcr Deutschland. Berlin: GKV-Spitzenverband; 2018."},{"key":"523_CR13","unstructured":"NICE Multiple Technology Appraisal\u2014Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs, London; 2017. \nhttps:\/\/www.nice.org.uk\/guidance\/ta445\/documents\/html-content-3\n\n (accessed 10 Aug 2019)."},{"key":"523_CR14","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV): Cosentyx ing\u00e5r i h\u00f6gkostnadsskyddet med begr\u00e4nsning, Stockholm; 2016. \nhttps:\/\/www.tlv.se\/beslut\/beslut-lakemedel\/begransad-subvention\/arkiv\/2016-05-31-cosentyx-ingar-i-hogkostnadsskyddet-med-begransning.html\n\n (accessed 10 Aug 2019)."},{"issue":"11","key":"523_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2217\/cer-2018-0075","volume":"7","author":"IB McInnes","year":"2018","unstructured":"McInnes IB, Nash P, Ritchlin C, Choy EH, Kanters S, Thom H, Gandhi K, Pricop L, Jugl SM. Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics\/apremilast: a network meta-analysis. J Comp Eff Res. 2018;7(11):1107\u201323.","journal-title":"J Comp Eff Res"},{"issue":"9227","key":"523_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356(9227):385\u201390.","journal-title":"Lancet"},{"issue":"7","key":"523_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2288-7-10","volume":"15","author":"BJ Shea","year":"2007","unstructured":"Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D, Bouter LM. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;15(7):10.","journal-title":"BMC Med Res Methodol"},{"key":"523_CR18","unstructured":"Rodgers M, Epstein D, Bojke L, Yang H, Craig D, Fonseca T, Myers L, Bruce I, Chalmers R, Bujkiewicz S, Lai M, Cooper N, Abrams K, Spiegelhalter D, Sutton A, Sculpher M, Woolacott N. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2011;15(10):i\u2013xxi, 1\u2013329."},{"issue":"15","key":"523_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2474-15-26","volume":"20","author":"MR Cawson","year":"2014","unstructured":"Cawson MR, Mitchell SA, Knight C, Wildey H, Spurden D, Bird A, Orme ME. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet Disord. 2014;20(15):26.","journal-title":"BMC Musculoskelet Disord"},{"key":"523_CR20","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen. General methods. Version 5.0. K\u00f6ln: IQWiG; 2017."},{"key":"523_CR21","unstructured":"Lauer-Fischer GmbH. Lauer-Taxe Arzneimittelpreise. \nhttp:\/\/www.lauer-fischer.de\n\n (accessed 1 June 2018)."},{"key":"523_CR22","volume-title":"Kosten der Unterversorgung mit Arzneimitteln in Deutschland","author":"R Rychlik","year":"2008","unstructured":"Rychlik R. Kosten der Unterversorgung mit Arzneimitteln in Deutschland. Februar: Gutachten f\u00fcr den Verband Forschender Arzneimittelhersteller e.V; 2008."},{"issue":"7","key":"523_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1610-0387.2005.05729.x","volume":"3","author":"K Berger","year":"2005","unstructured":"Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges. 2005;3(7):511\u20138.","journal-title":"J Dtsch Dermatol Ges"},{"key":"523_CR24","unstructured":"Kassen\u00e4rztliche Bundesvereinigung. Einheitlicher. Bewertungsma\u00dfstab. Stand: 1. Quartal 2018. Berlin; 2018."},{"key":"523_CR25","unstructured":"Robert Koch Institut. Bericht zum Krebsgeschehen in Deutschland 2016, Berlin; 2016."},{"key":"523_CR26","unstructured":"Statistisches Bundesamt (Destatis). Krankheitskosten 2015 in Deutschland nach Diagnosen, Einrichtungen, Alter und Geschlecht. Statistisches Bundesamt (Destatis); 2017."},{"key":"523_CR27","doi-asserted-by":"crossref","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Medical Care; 1997. p. 1095\u20131108.","DOI":"10.1097\/00005650-199711000-00002"},{"issue":"10","key":"523_CR28","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/art.1780401021","volume":"40","author":"K Wong","year":"1997","unstructured":"Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic I Causes and risk of death. Arthritis Rheumatol. 1997;40(10):1868\u201372.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"523_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","volume":"163","author":"K Abuabara","year":"2010","unstructured":"Abuabara K, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK. Br J Dermatol. 2010;163(3):586\u201392.","journal-title":"Br J Dermatol"},{"key":"523_CR30","unstructured":"Statistisches Bundesamt (Destatis). Sterbetafel (Periodensterbetafel): Deutschland, Jahre, Geschlecht, Vollendetes Alter. Statistisches Bundesamt (Destatis); 2018."},{"key":"523_CR31","volume-title":"Cost-effectiveness in health and medicine","author":"LA Prosser","year":"2016","unstructured":"Prosser LA, Neumann PJ, Sanders GD, Siegel JE. Reporting cost-effectiveness analyses. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG, editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 2016."},{"issue":"11","key":"523_CR32","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","volume":"72","author":"KM Fagerli","year":"2013","unstructured":"Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, R\u00f8devand E, Mikkelsen K, Lexberg AS, Kvien TK. Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis. 2013;72(11):1840\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"523_CR33","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, Lindegaard HM, Holland-Fischer M, Nordin H, Jensen DV, Olsen CH, Hetland ML. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheumatol. 2013;65(5):1213\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"523_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3899\/jrheum.161567","volume":"45","author":"LR Harrold","year":"2018","unstructured":"Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW, Malley W, Greenberg JD, Etzel CJ. Rebound in measures of disease activity and symptoms in Corrona Registry patients with psoriatic arthritis who discontinue tumor necrosis factor inhibitor therapy after achieving low disease activity. J Rheumatol. 2018;45(1):78\u201382.","journal-title":"J Rheumatol"},{"issue":"2","key":"523_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41927-018-0011-1","volume":"12","author":"V Strand","year":"2018","unstructured":"Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A. Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis. BMC Rheumatol. 2018;12(2):3.","journal-title":"BMC Rheumatol"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-019-00523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-019-00523-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-019-00523-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T00:10:55Z","timestamp":1604621455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-019-00523-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["523"],"URL":"https:\/\/doi.org\/10.1007\/s40258-019-00523-1","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,7]]},"assertion":[{"value":"7 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"DO is the founder and director of WifOR, which was contracted by Novartis Deutschland GmbH to undertake this work. AG is a consultant for WifOR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This work was contracted by Novartis Deutschland GmbH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}